Inclin
Inclin is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE).
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The screening period was extended to accommodate potential scheduling challenges for MRI assessments, repeat laboratory assessments, and genetic testing for familial chylomicronemia syndrome.
- Eligibility criteria were revised to specify diabetes-related exclusions, permit participants with previously treated non-active hepatitis C infection, clarify malignancy and beta-blocker criteria, and exclude recent or anticipated major changes in triglyceride-lowering therapies.
- Women of childbearing potential were required to use highly effective contraception from informed consent until at least 17 weeks after the last study-drug dose, based on updated pharmacokinetic modeling.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3 Open-Label Study of PTC923 (Sepiapterin) in Phenylketonuria
Sponsor PTC Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
ISIS 678354-CS9: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) in Patients with Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), or with Severe Hypertriglyceridemia
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
ISIS 721744-CS3: An Open-Label Extension Study of ISIS 721744 in Patients with Hereditary Angioedema
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAL02 ADMINISTERED INTRAVENOUSLY IN ADDITION TO STANDARD OF CARE IN SUBJECTS WITH SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
Sponsor Eagle Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Sponsor Prothena Biosciences Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Sponsor Ngm Biopharmaceuticals Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Inclin?
The 2026-10-09 snapshot links Inclin to 9 distinct CTIS trials. Recorded services include Data management, Investigator recruitment, Clinical monitoring, Data management support, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Inclin?
The most frequently recorded therapeutic areas are Allergy, Cardiology, Genetic and Congenital Disorders, Immunology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Inclin conducted?
The linked trials record locations in 24 countries, including Spain, France, Italy, Netherlands, Czechia. These are trial locations, not confirmed office locations or countries where Inclin delivered services.
What can this page tell me about Inclin's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Inclin. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- InClin Inc.
- Inclin Inc.